Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2002

View Archived Issues

Deltagen and Stanford University form research collaboration

First IND allowance for Copharos vitamin B12-based product

Birmingham 2002 EAU webcasts by Prous Science

HE-2500 effective in preclinical model of psoriasis; clinical trials planned

First multiple-dose clinical study of ERA-923 in healthy postmenopausal women

Conference presentation supports development of edaravone for neurodegenerative diseases

TP-10 fails to meet primary endpoint in phase II trial in adults undergoing cardiac surgery

Anadys and Structural GenomiX enter antibiotic drug discovery collaboration

Zevalin therapeutic regimen approved for NHL

GlaxoSmithKline launches environmentally friendly reformulation of Ventolin

Amarin and NanoCarrier to form nanoparticle delivery technology collaboration

Encouraging phase II results reported for T-20 in combination therapy

Zomig nasal spray formulation launched in Sweden

Maxygen and Lundbeck to advance interferon beta compound into clinical trials for MS

GeneTrove enters target validation collaboration with Merck

Pozen to submit rat carcinogenicity results for MT-100 during NDA review

Celltech prepares compounds with use in conditions mediated by the extravasation of leukocytes

Nongenotoxic porphyrin derivatives from Eukarion effective as ROS catalytic scavengers

Compounds for damaging newly formed vascular endothelium disclosed by Angiogene

WBC/HPC mobilization by fucoidan involves increases in circulating SDF-1

Researchers at the University of Edinburgh synthesize anticancer ruthenium complexes

Viral DNA polymerase inhibitors with utility against herpes and cytomegalovirus infections

Biochemie prepares mutilin derivatives with antibacterial activity

Pfizer claims pyrazole derivatives with potential in the treatment of HIV

Compounds with affinity for the benzodiazepine site of GABA-A receptors claimed by Neurogen

Orphan drug designation granted for 5G1.1 in membranous nephritis; phase II trial under way

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...